AKRO241220C32500
- 1.15
- -0.25-17.86%
Akero Therapeutics Newsroom
Morgan Stanley Maintains Akero Therapeutics(AKRO.US) With Buy Rating, Maintains Target Price $46
Akero Therapeutics Receives Buy Rating for Promising Efruxifermin Developments in MASH Treatment
H.C. Wainwright Maintains Akero Therapeutics(AKRO.US) With Buy Rating, Maintains Target Price $50
Akero Therapeutics Price Target Announced at $65.00/Share by Citigroup
Akero Therapeutics Analyst Ratings
Akero Therapeutics (AKRO) Receives a Buy From Phillip Securities
Promising Clinical Trial Results and Future Potential Justify Buy Rating for Akero Therapeutics
BofA Securities Initiates Akero Therapeutics(AKRO.US) With Hold Rating
Bank of America Securities Reaffirms Their Hold Rating on Akero Therapeutics (AKRO)
H.C. Wainwright Maintains Akero Therapeutics(AKRO.US) With Buy Rating, Maintains Target Price $50
Akero Therapeutics Price Target Maintained With a $50.00/Share by HC Wainwright & Co.
Akero Therapeutics Analyst Ratings
Morgan Stanley Maintains Akero Therapeutics(AKRO.US) With Buy Rating, Maintains Target Price $46
Evercore Maintains Akero Therapeutics(AKRO.US) With Buy Rating, Maintains Target Price $38
CCORF Maintains Akero Therapeutics(AKRO.US) With Buy Rating, Maintains Target Price $56
Morgan Stanley Maintains Akero Therapeutics(AKRO.US) With Buy Rating, Maintains Target Price $46
LifeSci Capital Maintains Akero Therapeutics(AKRO.US) With Buy Rating, Maintains Target Price $60
Buy Rating Reaffirmed for Akero Therapeutics: Strong Financials and Promising Clinical Trials Bolster Confidence
H.C. Wainwright Maintains Akero Therapeutics(AKRO.US) With Buy Rating, Maintains Target Price $50
Morgan Stanley Maintains Akero Therapeutics(AKRO.US) With Buy Rating, Maintains Target Price $46